Literature DB >> 21146391

Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases.

Derrick Sek Tong Ong1, Jeffery W Kelly.   

Abstract

Inheriting a mutant misfolding-prone protein that cannot be efficiently folded in a given cell type(s) results in a spectrum of human loss-of-function misfolding diseases. The inability of the biological protein maturation pathways to adapt to a specific misfolding-prone protein also contributes to pathology. Chemical and biological therapeutic strategies are presented that restore protein homeostasis, or proteostasis, either by enhancing the biological capacity of the proteostasis network or through small molecule stabilization of a specific misfolding-prone protein. Herein, we review the recent literature on therapeutic strategies to ameliorate protein misfolding diseases that function through either of these mechanisms, or a combination thereof, and provide our perspective on the promise of alleviating protein misfolding diseases by taking advantage of proteostasis adaptation.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21146391      PMCID: PMC3078197          DOI: 10.1016/j.ceb.2010.11.002

Source DB:  PubMed          Journal:  Curr Opin Cell Biol        ISSN: 0955-0674            Impact factor:   8.382


  38 in total

1.  Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis.

Authors:  Xiaodong Wang; John Venable; Paul LaPointe; Darren M Hutt; Atanas V Koulov; Judith Coppinger; Cemal Gurkan; Wendy Kellner; Jeanne Matteson; Helen Plutner; John R Riordan; Jeffery W Kelly; John R Yates; William E Balch
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

Review 2.  Chaperone-assisted folding of newly synthesized proteins in the cytosol.

Authors:  Elke Deuerling; Bernd Bukau
Journal:  Crit Rev Biochem Mol Biol       Date:  2004 Sep-Dec       Impact factor: 8.250

Review 3.  Molecular chaperones and protein quality control.

Authors:  Bernd Bukau; Jonathan Weissman; Arthur Horwich
Journal:  Cell       Date:  2006-05-05       Impact factor: 41.582

Review 4.  Therapeutic strategies to ameliorate lysosomal storage disorders--a focus on Gaucher disease.

Authors:  A R Sawkar; W D'Haeze; J W Kelly
Journal:  Cell Mol Life Sci       Date:  2006-05       Impact factor: 9.261

5.  Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.

Authors:  Anu R Sawkar; Martina Schmitz; Klaus-Peter Zimmer; David Reczek; Tim Edmunds; William E Balch; Jeffery W Kelly
Journal:  ACS Chem Biol       Date:  2006-05-23       Impact factor: 5.100

6.  Autophagosome maturation is impaired in Fabry disease.

Authors:  Marc Chévrier; Noureddine Brakch; Lesueur Céline; Damien Genty; Yasmina Ramdani; Solange Moll; Mojgan Djavaheri-Mergny; Carole Brasse-Lagnel; Annie Laquerrière Annie Laquerrière; Frédéric Barbey; Soumeya Bekri
Journal:  Autophagy       Date:  2010-07-01       Impact factor: 16.016

7.  Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease.

Authors:  Anu R Sawkar; Wei-Chieh Cheng; Ernest Beutler; Chi-Huey Wong; William E Balch; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

8.  Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive.

Authors:  G M Denning; M P Anderson; J F Amara; J Marshall; A E Smith; M J Welsh
Journal:  Nature       Date:  1992-08-27       Impact factor: 49.962

9.  Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor.

Authors:  J Q Fan; S Ishii; N Asano; Y Suzuki
Journal:  Nat Med       Date:  1999-01       Impact factor: 53.440

Review 10.  The mammalian unfolded protein response.

Authors:  Martin Schröder; Randal J Kaufman
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

View more
  28 in total

1.  The thiazide-sensitive NaCl cotransporter is targeted for chaperone-dependent endoplasmic reticulum-associated degradation.

Authors:  Patrick G Needham; Kasia Mikoluk; Pradeep Dhakarwal; Shaheen Khadem; Avin C Snyder; Arohan R Subramanya; Jeffrey L Brodsky
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

Review 2.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

3.  α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.

Authors:  Aleksandra Siekierska; Greet De Baets; Joke Reumers; Rodrigo Gallardo; Stanislav Rudyak; Kerensa Broersen; Jose Couceiro; Joost Van Durme; Joost Schymkowitz; Frederic Rousseau
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

4.  Cell-based high-throughput screening identifies galactocerebrosidase enhancers as potential small-molecule therapies for Krabbe's disease.

Authors:  Dae Song Jang; Wenjuan Ye; Tian Guimei; Melani Solomon; Noel Southall; Xin Hu; Juan Marugan; Marc Ferrer; Gustavo H B Maegawa
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

Review 5.  Autophagy and cartilage homeostasis mechanisms in joint health, aging and OA.

Authors:  Martin K Lotz; Beatriz Caramés
Journal:  Nat Rev Rheumatol       Date:  2011-08-02       Impact factor: 20.543

Review 6.  Expanding proteostasis by membrane trafficking networks.

Authors:  Darren M Hutt; William E Balch
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-07-01       Impact factor: 10.005

7.  ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease.

Authors:  Yun Lei Tan; Joseph C Genereux; Sandra Pankow; Johannes M F G Aerts; John R Yates; Jeffery W Kelly
Journal:  Chem Biol       Date:  2014-08-14

8.  A molecular imaging biosensor detects in vivo protein folding and misfolding.

Authors:  Anjali V Sheahan; Thillai V Sekar; Kai Chen; Ramasamy Paulmurugan; Tarik F Massoud
Journal:  J Mol Med (Berl)       Date:  2016-06-08       Impact factor: 4.599

9.  Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones.

Authors:  Chunzhang Yang; Cody L Swallows; Chao Zhang; Jie Lu; Hongbin Xiao; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-18       Impact factor: 11.205

10.  Targeting IRE1 with small molecules counteracts progression of atherosclerosis.

Authors:  Ozlem Tufanli; Pelin Telkoparan Akillilar; Diego Acosta-Alvear; Begum Kocaturk; Umut Inci Onat; Syed Muhammad Hamid; Ismail Çimen; Peter Walter; Christian Weber; Ebru Erbay
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.